17:55 , Oct 6, 2017 |  BC Week In Review  |  Financial News

SpecificiT completes seed financing

On Sept. 11, cancer company SpecificiT Pharma Inc. (Montreal, Quebec) said it completed an undisclosed seed financing in late August led by Sanderling Ventures . Accel-Rx Health Sciences Accelerator and founding investor AmorChem also participated....
18:38 , Nov 18, 2016 |  BioCentury  |  Emerging Company Profile

Suppressing somatostatin

Zucara Therapeutics Inc. is developing somatostatin receptor 2 antagonists to prevent hypoglycemia in Type I diabetes patients without decreasing the efficacy of insulin therapy. In Type I diabetes, somatostatin production is elevated, leading to continuous...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Financial News

ScarX completes venture financing

ScarX Therapeutics Inc. , Toronto, Ontario   Business: Dermatology   Date completed: 2016-02-16   Type: Venture financing   Raised: C$2 million ($1.4 million)   Investors: Accel-Rx Health Sciences Accelerator; BDC Capital; MaRS Innovation ; and...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Financial News

Encycle Therapeutics completes venture financing

Encycle Therapeutics Inc. , Toronto, Ontario   Business: Chemistry, Autoimmune, Cancer   Date completed: 2015-09-30   Type: Venture financing   Raised: C$2.9 million ($2.1 million)   Investors: Takeda Ventures Inc.; Accel-Rx Health Sciences Accelerator; BDC...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Accel-Rx Health Sciences Accelerator finance news

Accel-Rx, a pan-Canadian health sciences accelerator, announced its official launch after receiving a C$14.5 million ($13.1 million) award from the Canadian government's Centers of Excellence for Commercialization and Research (CECR) program. CDRD Ventures Inc. ,...